New Delhi, Feb. 28 -- The Indian Pharmaceutical Alliance (IPA), representing major Indian drug manufacturers, has suggested that the government consider reducing tariffs on US drug imports to zero.

This proposal comes as a countermeasure to the Trump administration's consideration of a 25 per cent import tariff on Indian pharmaceutical products.

According to IPA Secretary General Sudarshan Jain, the move would not significantly impact India's economy and could potentially persuade the US government to reconsider its tariff policies.

India currently exports pharmaceutical products worth USD 9 billion to the US, while US pharmaceutical exports to India stand at approximately USD 800 million.

Jain pointed out that 60 per cent of these US...